
Please try another search
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.
Name | Age | Since | Title |
---|---|---|---|
Paul Edward-Alexander Hopper | 67 | 2012 | Executive Chairman |
Leslie Chong | - | 2015 | CEO, MD & Executive Director |
Yelena Y. Janjigian | - | 2016 | Scientific Advisory Board Member |
Lesley Russell | 63 | 2019 | Independent Non-Executive Director |
Yuman Fong | - | 2019 | Chair of Oncolytic Virotherapy Scientific Advisory Board |
Tanios Bekaii-Saab | - | 2018 | Member of Scientific Advisory Board |
Prasad S. Adusumilli | - | 2019 | Member of Scientific Advisory Board |
Rebecca Auer | - | 2019 | Member of Scientific Advisory Board |
Neil H. Segal | - | 2014 | Member of Scientific Advisory Board |
Kimberlee Cobleigh Drapkin | 56 | 2023 | Non-Executive Director |
Peter Schmid | - | 2017 | Member of Scientific Advisory Board |
Josep Tabernero Caturla | - | 2018 | Member of Scientific Advisory Board |
Pravin T. P. Kaumaya | - | 2018 | Member of Scientific Advisory Board |
Jakob Dupont | 59 | 2022 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review